Archives
-
Patient-Derived Spheroids Model Localized Prostate Cancer
2026-09-24
Linxweiler and colleagues established viable, patient-derived three-dimensional spheroids from radical prostatectomy tissue, addressing a shortage of representative models for organ-confined prostate cancer. The cultures retained several prostate epithelial and androgen receptor markers, could be cryopreserved, and showed different responses to tested drugs—an important reminder that model context shapes pharmacologic results.
-
BIIE 0246: A Y2 Receptor Probe for Neural Research
2026-09-24
Use BIIE 0246 to isolate Y2-receptor contributions to NPY signaling in synaptic, feeding, and exploratory neurocardiac assays. A practical workflow pairs nanomolar concentration-response testing with receptor-aware controls—especially important because recent adipose-neural arrhythmia research implicates Y1R, not Y2R.
-
Calnexin Shapes CFTR Variant Rescue and Corrector Response
2026-09-23
A deep mutational scanning study of 232 clinical CFTR variants shows that calnexin supports CFTR surface expression and influences corrector rescue in a variant-dependent way. Its findings distinguish protein abundance from channel function and point to cellular quality control as an important variable in interpreting CFTR modulator responses.
-
LC–MS/MS Maps GS-441524 Prodrug Conversion
2026-09-23
A January 2026 Microchemical Journal study established an LC–MS/MS workflow to track conversion of the novel GS-441524 prodrug NGP-1 into GS-441524 across gastric, blood, microsomal, and rat pharmacokinetic models. Its findings suggest sequential conversion in the stomach, liver, and bloodstream, offering a framework for interpreting prodrug exposure without equating parent-drug concentrations with intracellular antiviral activity.
-
Cyanidin Chloride: Identity-First Assay Design
2026-09-22
Cyanidin Chloride can support rigorous oxidative stress research when chemical identity, redox chemistry, inflammation, and barrier readouts are interpreted together. This identity-first guide explains how to translate anthocyanin evidence without confusing cyanidin chloride with the glycoside evaluated in a recent psoriasis model.
-
Atorvastatin: Mechanism and Research Applications
2026-09-22
Atorvastatin is an oral HMG-CoA reductase inhibitor used in cholesterol metabolism research, vascular cell biology studies, and cardiovascular disease research. Product data and a 2025 peer-reviewed study support distinct research applications in smooth-muscle biology, abdominal aortic aneurysm inhibition, and ferroptosis-oriented hepatocellular carcinoma models.
-
CDC42–YAP–mTOR Control of Intestinal Stem Cell Fate
2026-09-21
Zhang et al. demonstrate that CDC42-dependent epithelial polarity controls the intestinal stem cell to transit amplifying cell transition through a YAP/TAZ–Ereg–mTOR signaling cascade. Their genetic and pharmacological experiments separate this polarity-dependent mechanism from canonical Wnt signaling and identify distinct effects on cell fate balance, crypt proliferation, and epithelial organization.
-
N1-Methylpseudo-UTP: From IVT to Translation
2026-09-21
N1-Methyl-Pseudouridine-5'-Triphosphate is more than a replacement nucleotide: it is a controllable variable in RNA structure, translation, and therapeutic performance. This thought-leadership analysis connects N1-Methylpseudo-UTP to chemically modified mRNA, intravesical lipid nanoparticle delivery, and the translational decisions that determine whether an in vitro transcription workflow can support development.
-
Cyanidin Chloride: From Redox Signal to Translation
2026-09-20
A mechanistic and strategic guide to using Cyanidin Chloride in identity-aware oxidative stress, inflammatory, and epithelial barrier research, with translational lessons from a 2024 HaCaT psoriasis model.
-
Filipin III: Mapping Cholesterol for MASLD Translation
2026-09-19
A thought-leadership guide to using Filipin III as a spatial cholesterol probe in MASLD research, connecting membrane organization with CAV1-dependent cholesterol homeostasis, ER stress, and pyroptosis while defining practical validation steps and translational limits.
-
TRIM66 and Monogenic Olfactory Receptor Choice
2026-09-18
The reference study identifies TRIM66 as an epigenetic repressor that helps convert initially polygenic olfactory receptor transcription into stable one-neuron-one-receptor expression. Its genetic, molecular, and behavioral evidence links enhancer repression to olfactory coding and provides a framework for designing follow-up studies of receptor choice and sensory-neuron maturation.
-
H5N1 mRNA Vaccine Protects Lactating Dairy Cows
2026-09-18
This study evaluates a hemagglutinin-encoding mRNA–lipid nanoparticle vaccine directly in high-yielding lactating dairy cows, addressing an important gap between platform development and field-relevant animal protection. The vaccine was well tolerated, induced strong antibody responses, and protected all immunized cattle after early high-dose challenge, while most animals remained protected months later despite low serum antibody levels.
-
Palonosetron: Pharmacology, PK, and Clinical Evidence
2026-09-17
The 2010 reference review presents palonosetron hydrochloride as a highly selective 5-HT3 receptor antagonist whose unusually strong receptor affinity and approximately 40-hour elimination half-life help explain sustained control of chemotherapy-related emesis. Its integrated binding, animal pharmacology, pharmacokinetic, and randomized clinical evidence supports noninferior acute protection and superior delayed protection compared with granisetron in the studied setting.
-
Cannabis Terpenes Activate A2A Receptors in Neuropathic Pain
2026-09-17
Schwarz and colleagues show that five Cannabis sativa terpenes reduce nociceptive hypersensitivity in mouse models of chemotherapy-induced peripheral neuropathy and inflammatory pain. The study combines behavioral pharmacology, spinal receptor knockdown, cAMP and binding assays, and computational modeling to identify adenosine A2A receptor activation as a key mechanism, while also finding no conditioned place preference.
-
D-N-Acetylgalactosamine: Protocol and QC Guide
2026-09-16
D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity reagent for aqueous workflows involving glycoprotein composition, brain heteropolysaccharides analysis, and related glycosylation studies. It is suitable for water or compatible DMSO preparations, but not for ethanol-based protocols or long-term storage of prepared solutions.